



## Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference

August 4, 2022

MENLO PARK, Calif.--(BUSINESS WIRE)--Aug. 4, 2022--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the 7<sup>th</sup> Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on Tuesday, August 16, 2022.

### About Personalis

Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The [Personalis NeXT Platform](#)® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis' [Clinical Laboratory](#) was built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the [Personalis website](#) and follow Personalis on [LinkedIn](#) and [Twitter](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220804005031/en/): <https://www.businesswire.com/news/home/20220804005031/en/>

Investor Relations Contact:  
Caroline Corner  
[investors@personalis.com](mailto:investors@personalis.com)  
415-202-5678

Media Contact:  
Jennifer Temple  
[pr@personalis.com](mailto:pr@personalis.com)  
[www.personalis.com](http://www.personalis.com)  
650-752-1300

Source: Personalis, Inc.